Hypercalcemia of Malignancy
📧 Sign up to get email alerts when something new happens for Hypercalcemia of Malignancy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-10-29FDA Approved: WYOST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for WYOST (denosumab) submitted by Sandoz Inc, expanding the product's indications.
-
FDA approval · 2025-10-29FDA Approved: STOBOCLO — Original Application (CELLTRION USA, Inc.)
FDA approved STOBOCLO (denosumab-BMWO) from Celltrion USA as an original application; a denosumab biosimilar with indications including oste…
-
FDA approval · 2025-10-29FDA Approved: ENOBY — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved ENOBY (denosumab-qbde) from Hikma Pharmaceuticals USA Inc. via an original biologics license application. ENOBY is a denosumab …
-
EMA approval · 2025-09-26EMA Authorised: Ibandronic acid Accord (ibandronic acid) — Accord Healthcare S.L.U.
The EMA authorised Accord Healthcare S.L.U.'s ibandronic acid product under a marketing authorization. The approval covers indications relat…
-
EMA approval · 2025-09-25EMA Authorised: Zoledronic acid Teva (zoledronic acid) — Teva B.V.
The EMA authorised Teva B.V.'s Zoledronic acid product for bone-related conditions and cancer-related bone disease. The active substance is …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-09-16FDA Approved: BOSAYA — Original Application (Biocon Biologics Inc.)
FDA approved BOSAYA (denosumab-kyqq) from Biocon Biologics Inc. under an Original Application as a biosimilar to denosumab products, with th…
-
EMA approval · 2025-08-11EMA Authorised: Zometa (zoledronic acid;zoledronic acid monohydrate) — Phoenix Labs Unlimited Company
The EMA has authorised Zometa (zoledronic acid) for cancer and bone-related indications, with Phoenix Labs Unlimited Company as the marketin…
-
FDA approval · 2025-02-28FDA Approved: STOBOCLO — Original Application (CELLTRION USA, Inc.)
FDA approved STOBOCLO (denosumab-BMWO) from Celltrion USA under an original Biologics License Application for multiple osteoporosis and canc…
-
FDA approval · 2024-03-05FDA Approved: WYOST — Original Application (Sandoz Inc)
FDA approved WYOST (denosumab) from Sandoz Inc under an original Biologics License Application.
-
FDA approval · 2023-06-05FDA Approved: ZOLEDRONIC ACID — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved Meitheal Pharmaceuticals' original application for zoledronic acid, enabling a generic IV bisphosphonate product. This mark…
-
FDA approval · 2023-03-08FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for zoledronic acid from Fresenius Kabi USA, LLC.
-
FDA approval · 2023-03-07FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for zoledronic acid submitted by Mylan Institutional LLC.
-
FDA approval · 2022-04-05FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for Zoledronic acid submitted by Sagent Pharmaceuticals, updating regulatory labeling per the su…
-
FDA approval · 2020-10-20FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Zoledronic acid from Hikma Pharmaceuticals USA Inc., indicating regulatory approval for the spon…
-
FDA approval · 2020-10-19FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for zoledronic acid from Mylan Institutional LLC under an abbreviated new drug application (ANDA), e…
-
FDA approval · 2020-02-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for Zoledronic acid from Dr. Reddy's Laboratories Limited, authorizing a generic product through…
-
FDA approval · 2020-02-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for zoledronic acid submitted by BluePoint Laboratories (ANDA205279).
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM [Phase 1, Phase 2]
A clinical trial update for JMT103 evaluating efficacy and safety in patients with refractory hypercalcemia of malignancy (Phase 1/Phase 2).
-
FDA approval · 2018-06-29FDA Approved: ZOLEDRONIC ACID — Original Application (Gland Pharma Limited)
The FDA approved an Original Application for a generic zoledronic acid product by Gland Pharma Limited.
-
FDA approval · 2017-07-07FDA Approved: RECLAST — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for RECLAST (zoledronic acid) submitted by Sandoz Inc.
-
FDA approval · 2017-02-02FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for zoledronic acid submitted by Sagent Pharmaceuticals, resulting in an approved labeling change. Z…
-
FDA approval · 2016-08-18FDA Approved: ZOLEDRONIC ACID — Original Application (Fresenius Kabi USA, LLC)
FDA approved an Original Application for Zoledronic acid as a generic injectable product from Fresenius Kabi USA, LLC. The approval covers i…
-
FDA approval · 2016-07-14FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for a generic zoledronic acid product from Heritage Pharmaceuticals (d/b/a Avet Pharmaceuticals)…
-
FDA approval · 2016-03-25FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for zoledronic acid filed by Sagent Pharmaceuticals.
-
FDA approval · 2015-11-19FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Zoledronic Acid from Hikma Pharmaceuticals USA Inc., resulting in a supplemental approval fo…